Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:CKT NASDAQ:CLBS NASDAQ:EYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCKTCricket Media GroupC$0.00C$0.07▼C$0.32N/AN/A607 shsN/ACLBSCaladrius Biosciences$6.37$0.38▼$1.24$26.05M0.91522,308 shs466,373 shsEYENational Vision$22.94-2.0%$24.11$9.56▼$25.67$1.82B1.232.42 million shs2.35 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLBSCaladrius Biosciences0.00%0.00%0.00%0.00%0.00%EYENational Vision0.00%-4.14%-5.25%+7.60%+117.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCKTCricket Media GroupN/AN/AN/AN/AN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AEYENational Vision2.836 of 5 stars2.32.00.03.33.50.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCKTCricket Media Group 0.00N/AN/AN/ACLBSCaladrius Biosciences 0.00N/AN/AN/AEYENational Vision 2.60Moderate Buy$24.737.79% UpsideCurrent Analyst Ratings BreakdownLatest CKT, CLBS, EYE, and DEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025EYENational VisionThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$17.00 ➝ $22.008/7/2025EYENational VisionWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$24.00 ➝ $27.008/7/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$30.00 ➝ $28.007/30/2025EYENational VisionRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.007/23/2025EYENational VisionWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $24.007/8/2025EYENational VisionUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.007/8/2025EYENational VisionNational BanksharesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$30.007/8/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$17.00 ➝ $30.006/18/2025EYENational VisionBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCKTCricket Media GroupN/AN/AN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/A$1.54 per shareN/AEYENational Vision$1.82B1.00$1.64 per share14.02$10.37 per share2.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCKTCricket Media GroupN/AN/A0.00N/AN/AN/AN/AN/AN/ACLBSCaladrius Biosciences-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/AEYENational Vision-$28.50M-$0.18N/A84.962.71-0.75%3.56%1.49%11/5/2025 (Estimated)Latest CKT, CLBS, EYE, and DEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025EYENational Vision$0.12$0.18+$0.06$0.11$469.21 million$486.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCKTCricket Media GroupN/AN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/AN/AEYENational VisionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCKTCricket Media GroupN/AN/AN/ACLBSCaladrius BiosciencesN/A22.3322.33EYENational Vision0.300.520.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCKTCricket Media GroupN/ACLBSCaladrius Biosciences15.57%EYENational VisionN/AInsider OwnershipCompanyInsider OwnershipCKTCricket Media GroupN/ACLBSCaladrius Biosciences2.20%EYENational Vision2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCKTCricket Media Group147,000N/AN/ANot OptionableCLBSCaladrius Biosciences2760.58 million59.25 millionOptionableEYENational Vision13,41179.20 million77.06 millionOptionableCKT, CLBS, EYE, and DEV HeadlinesRecent News About These CompaniesBrokerages Set National Vision Holdings, Inc. (NASDAQ:EYE) Target Price at $24.73September 1 at 2:01 AM | americanbankingnews.comInsider Selling: National Vision (NASDAQ:EYE) Chairman Sells 137,400 Shares of StockAugust 31 at 4:17 AM | americanbankingnews.comNational Vision Holdings, Inc. (NASDAQ:EYE) Receives Average Rating of "Moderate Buy" from BrokeragesAugust 31 at 3:10 AM | marketbeat.comNational Vision (NASDAQ:EYE) Chairman Sells $3,342,942.00 in StockAugust 30 at 6:53 AM | insidertrades.com310,138 Shares in National Vision Holdings, Inc. $EYE Bought by Nuveen LLCAugust 30 at 3:41 AM | marketbeat.comInvesco Ltd. Has $7.67 Million Stock Holdings in National Vision Holdings, Inc. $EYEAugust 28, 2025 | marketbeat.comNational Vision Holdings, Inc. $EYE Holdings Lowered by Penn Capital Management Company LLCAugust 26, 2025 | marketbeat.comKentuckians urged to prioritize their eye health during National Eye Exam MonthAugust 26, 2025 | hoptownchronicle.orgHIt's Still Early For National Vision HoldingsAugust 24, 2025 | seekingalpha.comNational Vision Holdings, Inc. $EYE Shares Bought by Charles Schwab Investment Management Inc.August 24, 2025 | marketbeat.comVanguard Group Inc. Grows Position in National Vision Holdings, Inc. $EYEAugust 24, 2025 | marketbeat.comChanning Capital Management LLC Takes Position in National Vision Holdings, Inc. $EYEAugust 23, 2025 | marketbeat.com22,162 Shares in National Vision Holdings, Inc. $EYE Purchased by Fox Run Management L.L.C.August 22, 2025 | marketbeat.comQ&A: AEVR's executive director on #SeeWhatMatters and safeguarding the National Eye InstituteAugust 21, 2025 | ophthalmologytimes.comOPublic Sector Pension Investment Board Buys 52,820 Shares of National Vision Holdings, Inc. $EYEAugust 21, 2025 | marketbeat.comNational Vision Announces Participation in Goldman Sachs Global Retailing ConferenceAugust 20, 2025 | businesswire.comAmerica's Best Unveils Major Brand Transformation: VML Relaunches Eye Care Retailer's Identity with the Powerful Message "Every Eye Deserves Better"August 19, 2025 | prnewswire.comBurgundy Asset Management Ltd. Raises Stake in National Vision Holdings, Inc. (NASDAQ:EYE)August 19, 2025 | marketbeat.comBoston Partners Reduces Stock Position in National Vision Holdings, Inc. (NASDAQ:EYE)August 18, 2025 | marketbeat.comDeutsche Bank AG Has $6.38 Million Stock Position in National Vision Holdings, Inc. (NASDAQ:EYE)August 18, 2025 | marketbeat.comKentuckians encouraged to prioritize eye health during National Eye Exam Month in AugustAugust 16, 2025 | nkytribune.comNMedia Sentiment Over Time Top HeadlinesView All HeadlinesD-Wave Delivers Growth Shock—Investors Eye Quantum FutureBy Nathan Reiff | August 8, 2025Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNXBy Leo Miller | August 6, 2025This Railroad Stock Is Chugging Along to a New All-Time HighBy Jordan Chussler | August 20, 2025Semtech: Bullish Market Forces Come Into Alignment for This StockBy Thomas Hughes | August 27, 2025DraftKings Posts Record Quarter, Eyes ProfitabilityBy Chris Markoch | August 8, 2025CKT, CLBS, EYE, and DEV Company DescriptionsCricket Media Group CVE:CKTCricket Media Group Ltd. (Cricket Media) is a United States-based education media company. The Company provides content on a learning network for children, families and teachers across the world. Its media brands for toddlers to teens include Babybug, Ladybug, Cricket and Cobblestone. The Company's products include magazines under categories, such as Ask, Cicada, Babybug, Click, Cricket, Cobblestone, Dig, Faces, Ladybug, Muse and Spider; educational toys; books; teacher guides; content library, and Story Bug application. Its Web-based K12 tools for school and home include the ePals community and virtual classroom for global collaboration, as well as In2Books, a Common Core eMentoring program that builds reading, writing and critical thinking skills. It serves teachers, students and parents in over 200 countries and territories through its platform and NeuPals, its joint venture with China-based information technology services company Neusoft.Caladrius Biosciences NASDAQ:CLBSCaladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.National Vision NASDAQ:EYE$22.94 -0.46 (-1.97%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$22.94 0.00 (0.00%) As of 08/29/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
